Navigation Links
CeNeRx BioPharma Completes $4.85 Million Financing
Date:12/9/2011

n the trial reveal regimen compliance rates of greater that 90%, with patients exhibiting therapeutic drug levels at all measured time points.  We look forward to reporting data from this TriRima Phase II trial during 2012."

Depression has long been associated with reductions in key neurotransmitters (serotonin, norepinephrine and dopamine), but only recently have researchers come to understand what causes their depletion.  New neuroimaging techniques have shown that these neurotransmitters are depleted due to the over- expression of monoamine oxidase A (MAO-A).  TriRima is the first and only medication that specifically blocks MAO-A, thereby allowing neurotransmitter levels to normalize.  This approach differs from traditional antidepressants, which seek to overcome low neurotransmitter levels primarily by concentrating the existing neurotransmitters in the gap between the neurons (the synaptic cleft), leaving the neurons themselves with a neurotransmitter deficit.  By blocking MAO-A and allowing the neurotransmitters to return to normal levels, TriRima acts to correct the neurotransmitter deficit both within the neuron and within the synaptic cleft.  TriRima's target is accordingly differentiated and upstream to the approach of most traditional classes of antidepressants, with the potential for improved efficacy.

TriRima is a selective and reversible member of a novel class of drugs known as RIMAs, or reversible inhibitors of monoamine oxidase A. TriRima acts to normalize the levels of three key neurotransmitters that positively affect mood and anxiety, and the selectivity and reversibility of TriRima are expected to eliminate or reduce the risk of food-associated cardiovascular effects of conventional MAO inhibitors.

Separately, CeNeRx announced that it has successfully filed an IND to assess CXB909 as a potential treatment for Alzheimer's disease.  CXB909, w
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Publication in Neuropsychopharmacology Confirms CeNeRxs Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A
2. CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors
3. CeNeRx BioPharma Completes $15 Million Series B Financing
4. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Windhover Announces the "Top Biopharma Projects to Watch"
7. Sutro Biopharma to Present its Biochemical Protein Synthesis Technology at BioProduction Conference 2011 in Berlin
8. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
9. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
10. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
11. Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... DIEGO , Nov. 20, 2014 ... has been dosed in its Phase 1 trial ... cisplatin for the treatment of malignant pleural mesothelioma ... Group is conducting clinical trials on ADI-PEG 20, ... agents, for the treatment of several other indications, ...
(Date:11/21/2014)... NEW YORK and SAN DIEGO ... CYTX ), today announced that President and CEO Marc Hedrick ... 2014. DATE:   Thursday, December 4, 2014 ... LINK:     Click here or paste this URL into ... is recommended that investors pre-register to save time and receive ...
(Date:11/18/2014)... 2014 Cord Blood Registry® (CBR®) announces ... Annual World Stem Cell Summit, the largest global meeting of ... Stem Cell Summit will be held December 3-5 at the ... The World Stem Cell Summit ... and therapies, convening the most prominent figures in the field ...
(Date:11/18/2014)... New Orleans, LA (PRWEB) November 17, 2014 ... developer of build-to-order, open architecture blade-based and rackmount ... new NVIDIA® Tesla® K80 dual-GPU accelerator throughout its ... Utilizing a pair of the company’s latest proprietary ... up to eight discrete NVIDIA Tesla K80 dual-GPU ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3
... DIEGO, Oct. 6 Gen-Probe Incorporated (Nasdaq: GPRO ... agreement to acquire Prodesse, Inc., a privately held leader ... for approximately $60 million in cash. Gen-Probe,s purchase ... Prodesse achieves certain financial and regulatory milestones in 2010 ...
... Oct. 6 Particle Sciences has ... to develop technology for a key Dow Corning product development ... remarked, "This is a little outside our normal focus of ... expect to provide a novel and robust solution that allows ...
... , ATLANTA, Oct. 6 CryoLife, Inc., ... and cardiovascular tissue processing company, today announced that it has ... and Drug Administration (FDA) for its CryoValve® SG aortic human ... in obtaining a Humanitarian Device Exemption (HDE) for the CryoValve ...
Cached Biology Technology:Gen-Probe to Acquire Prodesse, Leader in Molecular Testing for Respiratory Infectious Diseases, for $60 Million in Cash Plus Potential Milestone Payments 2Gen-Probe to Acquire Prodesse, Leader in Molecular Testing for Respiratory Infectious Diseases, for $60 Million in Cash Plus Potential Milestone Payments 3Gen-Probe to Acquire Prodesse, Leader in Molecular Testing for Respiratory Infectious Diseases, for $60 Million in Cash Plus Potential Milestone Payments 4Gen-Probe to Acquire Prodesse, Leader in Molecular Testing for Respiratory Infectious Diseases, for $60 Million in Cash Plus Potential Milestone Payments 5Particle Sciences, Inc. and Dow Corning Corporation Cooperate to Develop New Product Technology 2CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 2CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 3CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 4
(Date:11/21/2014)... 19, 2014  Earlier this year Donald Spector ... and one of the most prolific inventors in the ... transmitted from Smartphones to third party agencies. Spector envisioned ... one of the earliest known patents in this area. ... the military, child care, elder care and hospital applications. ...
(Date:11/21/2014)... , Nov. 20, 2014   Atmel® Corporation ... in microcontroller (MCU) and touch technology solutions, today launched ... sensors with the widest V cc range ... temperature accuracy and faster I 2 C bus communication ... serial EEPROM memory making them ideal for consumer, industrial, ...
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... seem, wastewater flushed down toilets and sinks is getting a ... to produce electricity, according to the latest video in the ... by the world,s largest scientific society, the video is at ... the video, points out that sewage treatment traditionally has been ...
... available in German . ... point to an infection with the bacterium Yersinia . ... apparatus called injectisome. For the first time, an international team ... Research (HZI) in Braunschweig, Germany, has unraveled this molecular syringe,s ...
... has been awarded a $2 million federal grant to ... that can be grown together to create a high-yield, ... National Science Foundation funding for the project begins ... effort will involve growing various combinations of lake algae ...
Cached Biology News:3-D molecular syringes 23-D molecular syringes 3U-M researchers land $2M grant to 'cooperate with nature' on growing algae for energy 2U-M researchers land $2M grant to 'cooperate with nature' on growing algae for energy 3U-M researchers land $2M grant to 'cooperate with nature' on growing algae for energy 4U-M researchers land $2M grant to 'cooperate with nature' on growing algae for energy 5
WTAP Antibody...
Anti-Dardarin Immunogen: Synthetic peptide from rat LRRK2. Available Date: 38814...
... MSY2/YBOX2 ( Abpromise for all ... Synthetic peptide derived from within ... Human MSY2/YBOX2. (Note: the amino ... (Peptide available as ab27460 ...
Request Info...
Biology Products: